Please assess the completion status of the following clinical trial:

Trial Title: Biweekly Avastin and Docetaxel as the First Line Treatment for Patients With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* written informed concent~* age \> or equal 18 years~* able to comply with the protocol~* histologically or cytologically confirmed, Her-2 negative, adenocarcinoma of the breast with measurable or nonmeasurable metastatic disease, chemotherapy indicated~* ECOG 0-2, life expectancy of over or qual to 12 wks~* prior neo/adjuvant chemotherapy allowed~* prior adjuvant taxane therapy is allowed, DFS\> or equal 6 months~* previous hormonal therapy allowed~* prior RT is allowed as adjuvant setting or to relief of metastatic bone pain, no more than 30% of marrow-bearing bone irradiated~* Adequate haematological function~* adequate liver function total bilirubin \<1.5 x upper limit of normal and AST,ALT \<2.5 x ULN in patients without liver metastases; \<5 x ULN in patients with liver metastases~* adequate renal function serum creatinine \<or equal 1,5x ULN or calculated creatinine clearance \> or equal 50mL/min and urine dipstick for proteinuria \<2+. Patients discovered to have or equal proteinuria or dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate \< or equal 1 g of protein in 24 hours~* INR\<or equal 1.5 and PTT\< or equal 1.5 x ULN within 7 days prior to enrolment. Anticoagulation treatment not allowed~* if female, should not be pregnant or breast-feeding. Women with an intact uterus must have a negative serum pregnancy test within 28 days prior to inclusion into the study~Exclusion Criteria:~* previous chemotherapy for mBC~* radiation therapy for the treatment of metastatic disease within 28 days~* evidence of CNS metastases. If symptomatic, the patient should be scanned within 28 days to enrolment to rule out CNS metastases~* pre-existing peripheral neuropathy NCI CTC-AE grade \> 2 at enrolment~* major surgery, significant traumatic injury within 28 days prior to enrolment or anticipation of the need for major surgery during study treatment~* Minor surgery, including insertion off an indwelling catheter, within 24 hours prior to the first line bevacizumab infusion~* Current or recent(within 10 daÿs of first dose of bevacizumab) use of aspirin (\>325mg/day)~* current or recent (within 10 days of first dose of bevacizumab) use of oral or parenteral anticoagulants or thrombolytic agents.~* history of evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding~* uncontrolled hypertension (systolic \>150mmHg and/or diastolic\>100mmHg)~* Clinically significant cardiovascular disease for example CVA, myocardial infarction, unstable angina, congestive heart failure NYHA Class \> or equal II, serious cardiac arrhythmia requiring medication during the study, which might interfere with regularity of the study treatment, or not controlled by medication~* non- healing wound, active peptic ulcer or bone fracture~* history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months of enrolment~* past of current history (within the last 5 years) of other malignancies except curatively treated basal and squamous cell carcinoma of the skin or in-situ carcinoma of the cervix~* treatment with any other investigational agent, or participation in another clinical drug trial within 28 days prior to enrolment~* evidence of any other disease, neurological, psychiatric or metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment-related complications~* history of thrombotic disorders within last six months

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- chemoterapy (Type: EXPERIMENTAL): docetaxel/paclitaxel + bevacizumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues